FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114767935> ?p ?o ?g. }

• W2114767935 endingPage "S12" @default.
• W2114767935 startingPage "S11" @default.
• W2114767935 abstract "Pompe disease is a rare neuromuscular disorder caused by a deficiency of the lysosomal enzyme acid c~-glucosidase. It is characterized by a broad clinical spectrum, ranging from a severe infant phenotype associated with generalized muscle weakness, hypertrophic cardiomyopathy, and death within the first year of life, to a slowly progressive adult form in which the heart is not affected. Enzyme replacement therapy (ERT) with recombinant human acid c~-glucosidase (alglucosidase alfa [Myozyme ®, Genzyme Corporation, Cambridge, Massachusetts]) for the treatment of Pompe disease received marketing approval in Europe and the United States in spring 2006. Before its approval, several studies evaluating the safety and efficacy of ERT were conducted, and a placebo-controlled study involving 90 adult patients with Pompe disease is currently ongoing. The first pilot studies on the use of ERT in infants with Pompe disease started in 1999.1,2 In the following years, more studies were carried out, which finally led to the approval of ERT for the treatment of Pompe disease. 2-7 These studies showed that ERT substantially reduces cardiac hypertrophy and increases survival times. Untreated patients usually died during their first year of life, whereas life expectancy was greatly prolonged in treated patients--the oldest surviving patients are now 9 years old. Several patients who were treated with ERT also gained muscle strength and reached developmental milestones such as sitting, crawling, and walking. These results suggest that early initiation of treatment is essential for a good outcome. The best response was seen in those patients who started treatment early, before irreversible damage occurred, while the majority of patients who started treatment at a later stage in the disease became ventilator dependent or eventually died. A study assessing preand posttreatment muscle pathologic findings reported more severe ultrastructural damage of myocytes in patients who did not respond to ERT, compared with those who were responsive to therapy. 8 Reports on ERT in patients with the more attenuated form of the disease are scarce; however, 2 preliminary studies, including 3 and 5 patients, respectively, have provided the first evidence that ERT is able to change the natural course of this form of the disease. 9,1° Despite the natural course of Pompe disease being one of progressive deterioration, 6 patients showed improvements in pulmonary and/or muscle function, and 2 patients' conditions stabilized after initiation of treatment. These results corroborate those found in infants I-7 and further indicate that the best outcome is obtained when treatment is initiated before the onset of severe muscle damage. However, larger studies are required to confirm these findings. To ensure a good outcome for patients, in addition to ERT, supportive measures--including physiotherapy, training, nutrition, and timely installation of (nightly) mechanical ventilation--need to be addressed." @default.
• W2114767935 created "2016-06-24" @default.
• W2114767935 creator A5042608565 @default.
• W2114767935 date "2008-01-01" @default.
• W2114767935 modified "2023-09-27" @default.
• W2114767935 title "Pompe Disease in Children-Early to Mid-stage" @default.
• W2114767935 cites W1969555423 @default.
• W2114767935 cites W1971873142 @default.
• W2114767935 cites W1978337429 @default.
• W2114767935 cites W2001805850 @default.
• W2114767935 cites W2070666959 @default.
• W2114767935 cites W2083572253 @default.
• W2114767935 cites W2099289539 @default.
• W2114767935 cites W2109581185 @default.
• W2114767935 cites W2132424400 @default.
• W2114767935 cites W2152085236 @default.
• W2114767935 cites W2250101192 @default.
• W2114767935 doi "https://doi.org/10.1016/s0149-2918(08)80024-0" @default.
• W2114767935 hasPublicationYear "2008" @default.
• W2114767935 type Work @default.
• W2114767935 sameAs 2114767935 @default.
• W2114767935 citedByCount "0" @default.
• W2114767935 crossrefType "journal-article" @default.
• W2114767935 hasAuthorship W2114767935A5042608565 @default.
• W2114767935 hasConcept C126322002 @default.
• W2114767935 hasConcept C146357865 @default.
• W2114767935 hasConcept C151730666 @default.
• W2114767935 hasConcept C187212893 @default.
• W2114767935 hasConcept C2779134260 @default.
• W2114767935 hasConcept C71924100 @default.
• W2114767935 hasConcept C86803240 @default.
• W2114767935 hasConceptScore W2114767935C126322002 @default.
• W2114767935 hasConceptScore W2114767935C146357865 @default.
• W2114767935 hasConceptScore W2114767935C151730666 @default.
• W2114767935 hasConceptScore W2114767935C187212893 @default.
• W2114767935 hasConceptScore W2114767935C2779134260 @default.
• W2114767935 hasConceptScore W2114767935C71924100 @default.
• W2114767935 hasConceptScore W2114767935C86803240 @default.
• W2114767935 hasLocation W21147679351 @default.
• W2114767935 hasOpenAccess W2114767935 @default.
• W2114767935 hasPrimaryLocation W21147679351 @default.
• W2114767935 hasRelatedWork W1989579502 @default.
• W2114767935 hasRelatedWork W2082482010 @default.
• W2114767935 hasRelatedWork W2178373740 @default.
• W2114767935 hasRelatedWork W2356105190 @default.
• W2114767935 hasRelatedWork W2383775094 @default.
• W2114767935 hasRelatedWork W2410491650 @default.
• W2114767935 hasRelatedWork W2604682584 @default.
• W2114767935 hasRelatedWork W2994700791 @default.
• W2114767935 hasRelatedWork W4231803726 @default.
• W2114767935 hasRelatedWork W4242858705 @default.
• W2114767935 hasVolume "30" @default.
• W2114767935 isParatext "false" @default.
• W2114767935 isRetracted "false" @default.
• W2114767935 magId "2114767935" @default.
• W2114767935 workType "article" @default.